R&D channel feed

There’s one end­point that the boom­ing bio­phar­ma in­dus­try has failed at mis­er­ably: fi­nan­cial tox­i­c­i­ty

6 years ago
Bioregnum
Opinion

Aca­di­a's sweep­ing hunt for bet­ter Nu­plazid da­ta bags mixed re­sults for schiz­o­phre­nia

6 years ago

OPDP let­ter crit­i­cizes drug com­pa­ny for fail­ing to dis­close risk in­fo on­line

6 years ago

La Jol­la CEO de­camps just as biotech faces a reck­on­ing for iron over­load drug

6 years ago

Make that 2 new sick­le cell dis­ease block­buster hope­fuls OK’d by the FDA in just a few days

6 years ago
FDA+

CymaBay scraps key NASH, PSC pro­grams af­ter lead drug trig­gers safe­ty alarms — share price im­plodes

6 years ago

Ex-Pur­due CEO stands to earn a huge wind­fall in No­var­tis' buy­out of the Med­i­cines Co

6 years ago
People
Deals

‘Break­through’ blad­der can­cer drug spin­out gets $570M to back launch of a new gene ther­a­py in the US

6 years ago
Startups
Deals

Roche, PTC will now get an FDA de­ci­sion on their SMA drug in 6 months — fac­ing off with Bio­gen, No­var­tis

6 years ago
FDA+

Roche shows Tecen­triq/Avastin com­bo helps liv­er can­cer pa­tients live longer

6 years ago
China

Har­vard con­sor­tium blue­prints $50M cell and gene ther­a­py cen­ter — but can they ac­tu­al­ly fos­ter low­er drug prices?

6 years ago

Ac­quis­i­tive No­var­tis bags PC­SK9 play­er Med­Co for $9.7B, set­ting up a flank at­tack on Sanofi, Re­gen­eron and Am­gen

6 years ago
Deals

With lat­est 18-month da­ta cut, Take­da push­es to­ward 2021 launch of dengue vac­cine — can they side­step Sanofi's dis­as­ter?

6 years ago

Take­da an­nounces pos­i­tive new ALK+ lung can­cer da­ta as list of crizo­tinib suc­ces­sors widens

6 years ago

Alexan­dria is think­ing big as it lays out plans for 1.6M square foot Bay Area biotech cam­pus

6 years ago

Put on hold mu­sic: Roche de­lays Spark buy­out for the 9th — and quite pos­si­bly not the last — time

6 years ago

As­traZeneca scores again: Calquence ap­proved for CLL as BTK race heats up

6 years ago

New epilep­sy com­pa­ny on the block wins FDA ap­proval for made-in-Ko­rea drug to treat fo­cal seizures

6 years ago
FDA+

Bio­gen's Al San­drock says the FDA needs to ap­prove their con­tro­ver­sial Alzheimer's drug — now

6 years ago
Bioregnum
Opinion

Genap­sys fi­nal­ly un­veils vaunt­ed se­quencer, but can it dent Il­lu­mi­na?

6 years ago

The triple crown in biotech: An all-or-noth­ing bet on an FDA ap­proval of 3 drugs over 16 months starts to­day

6 years ago

No­var­tis, Bay­er, Long­wood back ge­nomics start­up to speed search for im­munother­a­py tar­gets

6 years ago
Startups

Can­cer Re­search UK spin­off rais­es $41M+ in Se­ries B in­jec­tion

6 years ago
Financing
Startups

Mor­phoSys’ chief sci­en­tist hits the ex­it, trig­ger­ing R&D re­or­ga­ni­za­tion as they shift fo­cus to US in an­tic­i­pa­tion of loom­ing FDA ap­proval

6 years ago
People
First page Previous page 221222223224225226227 Next page Last page
A service from the Financial Times